In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $347.83, marking a +0.03% move from the previous day.
Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.
Let's look at two stocks that fit this description: Vertex Pharmaceuticals (NASDAQ: VRTX) and Visa (NYSE: V). One of the keys to success as a biotech company is to develop medicines for diseases that are at least as good as the existing standards of care. Vertex Pharmaceuticals' goal goes further.